Trial · NCT04006457
Results by group436
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 436
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 401 | Participants | ||
| Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 515 | Participants | ||
| Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | SAEs | 30 | Participants | |
| Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | SAEs | 42 | Participants | |
| Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | AEs Leading to Discontinuation | 36 | Participants | |
| Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | AEs Leading to Discontinuation | 46 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Diastolic blood pressure (mmHg): value <50 | 11 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Diastolic blood pressure (mmHg): value <50 | 15 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Diastolic blood pressure (mmHg): change >=20 increase | 39 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Diastolic blood pressure (mmHg): change >=20 increase | 70 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Diastolic blood pressure (mmHg): change >=20 decrease | 45 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Diastolic blood pressure (mmHg): change >=20 decrease | 51 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Pulse rate (bpm): Value <40 | 1 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Pulse rate (bpm): Value <40 | 3 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Pulse rate (bpm): Value >120 | 0 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Pulse rate (bpm): Value >120 | 1 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Systolic blood pressure (mmHg): Value <90 | 13 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Systolic blood pressure (mmHg): Value <90 | 30 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | Systolic blood pressure (mmHg): change>=30 increase | 18 | Participants | |
| Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up Visit | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | Systolic blood pressure (mmHg): change>=30 increase | 42 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04006457/results